FAB Fusion Antibodies Plc

TIDMFAB

RNS Number : 6805J

Fusion Antibodies PLC

21 August 2019

Fusion Antibodies plc

("Fusion" or the "Company")

Posting of Annual Report and Notice of AGM

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019 ('2019 Annual Report and Accounts'), the Notice of Annual General Meeting ('AGM') and a Form of Proxy will be posted to shareholders later today.

The AGM will be held on 20 September 2019 at 11.00 a.m. at Riddel Hall, Queens University, 185 Stranmillis Road, Belfast BT9 5EE United Kingdom.

A copy of the 2019 Annual Report and Accounts will be available to download from the Company website shortly.

Enquiries:

 
 Fusion Antibodies plc                                  www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                           Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                Tel: +44 (0)20 3328 5656 
 James Reeve / Asha Chotai 
 
 Walbrook PR                   Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                            Mob: +44 (0)7876 741 001 
 Paul McManus                                           Mob: +44 (0)7980 541 893 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 150 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of between 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAZMGZRDGZGLZM

(END) Dow Jones Newswires

August 21, 2019 02:00 ET (06:00 GMT)

Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024